Zobrazeno 1 - 2
of 2
pro vyhledávání: '"Ann Søegaard Knop"'
Autor:
Diogo Martins-Branco, Marie Kassapian, Véronique Debien, Rafael Caparica, Daniel Eiger, Urania Dafni, Charitini Andriakopoulou, Sarra El-Abed, Miguel Izquierdo, Malou Vicente, Saranya Chumsri, Martine Piccart-Gebhart, Alvaro Moreno-Aspitia, Ann Søegaard Knop, Janine Lombard, Evandro de Azambuja
Publikováno v:
Cancer Research. 82:P1-14
Background: The erythropoietin (EPO) receptor activation can stimulate tumor proliferation and may be implicated in resistance to anti-HER2 therapies. EPO administration can be used for the management of chemotherapy-induced anemia. We aim to assess
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::38b1aa9f69b7548899bba0fc274f8dcd
https://doi.org/10.1158/1538-7445.sabcs21-p1-14-05
https://doi.org/10.1158/1538-7445.sabcs21-p1-14-05
Autor:
Ida Kappel Buhl, Troels Dreier Christensen, Anna Sofie Kappel Buhl, Ib Jarle Christensen, Eva Balslev, Ann Søegaard Knop, Bent Ejlertsen, Iben Kümler, Hella Danø, Adam Andrzej Luczak, Sven Tyge Langkjer, Søren Linnet, Erik Hugger Jakobsen, Jurij Bogovic, Vesna Glavicic, Ulla Hald Buhl, Steen Knudsen, Peter Buhl Jensen, Dorte Nielsen
Background Even with positive oestrogen receptor (ER+) status some advanced breast cancer (ABC) patients fail to benefit from endocrine therapy (ET). A method that previously predicted other drugs in various cancers was evaluated. Here multigene mark
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1f74f0164074f9f5c285dc7b7b2cb16b
https://doi.org/10.21203/rs.2.10981/v1
https://doi.org/10.21203/rs.2.10981/v1
